Pharma Journalist -

AMRI, a global contract research and manufacturing organization working to improve patient outcomes and quality of life, has entered an alliance with Bruker Daltonics and HighRes…
Read More...

GW Pharmaceuticals has unveiled positive top-line results from an exploratory Phase 2 placebo-controlled clinical study of a combination of tetrahydrocannabinol (THC) and cannabidiol…
Read More...

Jazz Pharmaceuticals plc \announced that the first patient has been enrolled in a Phase 2 clinical study evaluating JZP-110, a selective dopamine and norepinephrine reuptake inhibitor,…
Read More...

Quotient Clinical announces that it has acquired SeaView Research, expanding its operations into the USA. The acquisition combines Quotient and SeaView’s complementary customer…
Read More...

Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced that the U.S.…
Read More...

Strata Oncology announced an agreement with Epizyme to support patient identification and enrollment for Epizyme’s ongoing Phase 2 clinical trial of tazemetostat in patients with…
Read More...

Veeva Systems (VEEV) announced a new cloud application dubbed Veeva Vault Submissions Publishing that incorporates publishing capabilities within Veeva Vault RIM to accelerate…
Read More...

Portola Pharmaceuticals, Inc.® (PTLA) announced that it has signed a $150 million royalty agreement with HealthCare Royalty Partners (HCR). Under the terms of the agreement, Portola…
Read More...

Teva Pharmaceutical Industries Ltd., announced that it has filed an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market…
Read More...

Lysogene announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to LYS-GM101, the company’s gene therapy drug candidate for treatment of GM1…
Read More...